Background: Systemic lupus erythematosus (SLE) is a multisystemic disease, caused by a variety of factors, which lead to immunological abnormalities. Osteopontin (OPN) is a pleiotropic protein, important in bone remodeling and immune system signaling. It produced by various cells, including immune cells, and played a key role in regulating T-helper 1/T-helper 2 balances, stimulating B lymphocytes to produce antibodies, regulating macrophages, neutrophils and inducing dendritic cells. Over expression of OPN has been associated with the pathogenesis of immune-mediated diseases. Objectives: To investigate the role of osteopontin in SLE and to assess its relation to disease activity and subclinical atherosclerosis. Subjects and Methods: This cross sectional case control study was conducted on 30 SLE patients fulfilling SLICCA /ACR criteria for SLE classification and 30 subjects sex-and agematched apparently healthy as control group. All patients were assessed for SLE disease activity by the systemic lupus activity Index (SLEDAI). Serum OSP and Doppler ultrasound for carotid artery media thickness (CIMT) were measured in all patients and control. Results: Plasma OPN levels were significantly higher in SLE patients than in control group (P<0.001) and had significant positive correlation with disease activity (r 0,595, P<0.05) and CIMT (r = 0.400, P <0.001), but there was no significant correlation between CIMT and disease activity. Conclusion: serum level of OPN was higher in SLE patients and correlated with disease activity and CIMT, and can be used as a marker of subclinical atherosclerosis.
INTRODUCTION
Systemic lupus erythematosus (SLE) is a chronic, autoimmune disease resulting from an interaction of genetic, environmental, and hormonal factors and characterized by a spectrum of clinical forms with a variable evaluation from a localized cutaneous form to life-threatening systemic form. It is a prototypic systemic autoimmune disease characterized by various immunological abnormalities, including dysregulated activation of both T and B lymphocytes with the production of a large quantity of autoreactive antibodies (1) . Deregulation of B and T lymphocytes activation leads to production of autoantibodies and abnormalities in cytokine expression. These autoantibodies [against double-stranded DNA (ds-DNA), SS-A (anti-Ro), SS-B (anti-La), anti-Sm, anti-RNP] form complexes with antigens, which are deposited in organs, cause inflammation and tissue damage (2, 3) . Deregulation in cytokine expression followed by inflammatory processes is also a cause of tissue injury. It was demonstrated that interleukin (IL)-6, B lymphocytes stimulators, IL-17, IL-18 and interferon (IFN)-α have the pathogenic role in SLE (4) . Osteopontin (OPN, early T-lymphocyte activation protein 1, Eta-1) is a secreted phosphorylated glycoprotein expressed in mineralized tissues (bone and teeth) and damaged renal tissues (5) . It is involved in normal physiological processes and is implicated in pathogenesis of variety of disease states, including atherosclerosis, cancer, glomerular nephritis and several chronic inflammatory diseases (6) . OPN appears to regulate innate immune cells and adaptive immune cells at multiple levels, its functions as a Th 1(T -helper 1) cytokine, promotes cellmediated immune responses and plays a role in chronic inflammatory diseases (7) . Increased plasma concentration, protein expression and local production of OPN have been observed in sepsis, metastasis, multiple sclerosis, autoimmune/ lymphoproliferative syndrome, renal tissue of SLE patients and joints of patients with rheumatoid arthritis (8) . High circulating OPN levels predicted increased cumulative disease activity and organ damage in both pediatric and adult SLE patients (9) . Atherosclerosis is a chronic inflammatory disease which is triggered by a proinflammatory process including endothelial dysfunction and high levels of circulating cholesterol. This is followed by lipid-laden macrophage (foam cell) accumulation in the subendothelial space of damaged endothelium within the vascular wall of medium-and/or small-sized arteries (10) . OPN is found at the site of atherosclerotic lesions, especially in association with macrophages and foam cells, suggesting that OPN plays an important role in the development and progression of atherosclerosis, vascular remodeling, and restenosis (11) . OPN levels are associated with atherosclerosis and coronary artery disease, and in these plaques, serve as a chemotactic agent for infiltrating macrophages (12) . Increase in carotid intima-media thickness (CIMT) is associated with atherosclerotic risk factors. CIMT is proposed to demonstrate the subclinical atherosclerosis (13) . In the present years, CIMT measurement is used to estimate the risk of myocardial infarction, stroke, and sudden cardiac death (14) .
SUBJECTS AND METHODS
This study was conducted on thirty SLE patients (Group I) fulfilling SLICCA /ACR 2012 criteria for SLE classification in addition to thirty sex-and agematched apparently healthy volunteers as control group (Group II). Patients were selected from rheumatology outpatient's clinic of AL-Zahraa hospital, Cairo, Egypt, during the period from December 2015 to June 2016. All patients gave their informed consents prior to their inclusion in the study. SLE patients were divided into two groups according to disease activity index (SLEDAI), Group Ia: Active SLE patients included 19 patients who SLEDAI >6 points. Group Ib: Inactive SLE patients included 11 patients who SLEDAI <6 points. We have excluded patients with other autoimmune rheumatological diseases, malignancy, patients with history of myocardial infarction. All patients were subjected to the following: Full medical history, general and rheumatologic examination: including age, disease duration, and drug treatment in use. Assessment of disease activity for patients by the systemic lupus disease activity index (SLEDAI) (15) .
Laboratory studies
Complete blood count (CBC), ESR determined by using (cell counter sysmex KX21N, Siemens, Germany), kidney functions (urea ,creatinine), liver function and serum lipids (Cholesterol, triglyceride, HDL, LDL), were done using (Cobas C311, Roche, Germany). Twenty four hour urine collection for measurement of urinary protein and creatinine clearance were done using (Cobas C311, Roche, Germany).
Immunological tests
Antinuclear antibody (ANA), Antidoule stranded DNA (AntidsDNA) were determined by (indirect immunofluresence technique using immunofluresence microscope (ZEISS-Axiolabe-Ser.Nr.994869) and the kit was supplied from Biorade USA).
Serum ostepontin
Was measured by quantitative sandwich enzyme immunoassay technique supplied from CUSABIO with Catalog Number.CSB-E04692h; using AS 1851 (reader) and 9809 for Das; Italy (washer).
Carotid Intima Media Thickness (CIMT)
CIMT was done by color Doppler ultrasound (Siemens Acuson X300, 7 MHz linear probe) on both sides, had been performed by the same examiner. CIMT was assessed at three levels on each side: common carotid artery (10 mm before the bulb), bulb (5-10 mm cranially to the start of the bulb) and internal carotid artery (10 mm after the flow divider); mean CIMT (m-CIMT) was defined as the mean of the three CIMT measurements on each side, while the maximum CIMT, the highest CIMT value found among the six segments studied (18) . According to current sonographic criteria, we refer to "normal" CIMT when complex intima-media is <0.9 mm; the CIMT>0.9 mm was considered indicative of thickened intima, while >1.3 mm indicative of atherosclerotic plaque(16).
Fig 1: Carotid Doppler ultrasound in one of SLE patients

Stastistical Analysis
Results were collected and analyzed by personal computer (excel 2010) and statistical package for social science (SPSS) version 16. Parametric data were expressed as mean and standard deviation (SD). Comparing the mean ±SD between two groups was done using student t-test. Also, Pearson Correlation Coefficient (r) used to measure the association between two quantitative variables. The Level of significance was set as P-value <0.05.
RESULTS
The current cross sectional study enrolled thirty SLE patients (group I) diagnosed according to SLICCA /ACR criteria and thirty apparently healthy persons who served as a control group (group II). SLE patients were 29 females (96.5%) and one male (3.5%), their ages ranged from 17 to 35 years with mean (26.5 ± 6.22) and duration of disease ranged from 1 to 10 years with mean ± SD (4.067±2.211). Control group were 28 females (93.3%) and 2 male (6.7%), their ages ranged from 18 to 36 years with mean ± SD (27.06 ± 4).
The frequency of various clinical manifestations in SLE patients (group I) are shown in (Table 1) (Table 2 ).
There were significant increase of mean OSP level in active SLE patients (group Ia) when compared to inactive SLE patients (group Ib) ( Table 3) . There were statistically significant positive correlation between OPN and disease activity, CIMT in 30 SLE patients (group I) (r value 0.595, 0.400, P value<0.05) respectively (Fig 3,4) and a highly statistically significant negative correlation with HDL (r -0.557, p<0.001) while there were no statistical significant correlation between OPN and disease duration, albumin, cholesterol, TG, creatinine clearance and 24 h urine protein (Table 4) . CIMT were positively correlated with disease duration (r 0.706, p<0.05) and cholesterol (r value 0.439, p<0.01) while not correlated with age, HDL,TG or SLEDAI (Table 5 ) (Fig 5) . Cut off value of serum osteopontin in 30 SLE patients were >14.2 with sensitivity 63.3% and specificity 100% ( 
Fig 2: Comparison between serum OPN in SLE patients (group I) and control group (group II)
DISCUSSION
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease, characterized by production of multiple autoantibodies, complement activation and immune-complex deposition causing tissue and organ damage (17) . Deregulation of B and T lymphocytes activation leads to production of autoantibodies and abnormalities in cytokine expression(3). Osteopontin (OPN, early T-lymphocyte activation protein, Eta-1) is a secreted phosphorylated glycoprotein expressed in mineralized tissues (bone and teeth) and damaged renal tissues. During inflammation, OPN is expressed by cells of both innate and adaptive immunity, such as natural killer (NK) cells, activated T cells, macrophages and fibroblasts (18) . OPN can enhance the Th1-mediated inflammatory process, activation of NK and T cells, and macrophage migration in the exacerbation of SLE9.This study was done to assess the relation between plasma osteopontin level and SLE disease activity and subclinical atherosclerosis. This study was done on 30 SLE patients who fulfilling SLICCA criteria 2012 with 30 healthy subjects as a control. They were classified according to disease activity into active group (19 patients) and inactive group (11 patients). Our results showed that there was statistical significant increase in mean serum level of OPN in SLE patients compared to control group and the elevation correlated positively with SLEDAI and there were significant increase of OSP level in active SLE patients (19 patients) when compared to inactive SLE patients (11 patients) . This in agreement with Lee and Song meta-analysis who did study on 1938 SLE patients revealed a significantly higher circulating OPN level in SLE patients with positive correlation between OPN levels and SLE activity (19) . Similarly, other study done on fifty four Chinese found that serum OPN concentrations were significantly higher in systemic lupus erythematosus (SLE) patients with renal impairment and in SLE patients than controls. Increase in OPN correlated significantly with SLE disease activity index in all patients. OPN production could be associated with the inflammatory process of SLE development and may serve as a potential disease marker of SLE (20) . Also Afify et al. (21) study was done on 40 children with SLE and 30 matched controls. The study showed that OPN concentrations were significantly higher in SLE patients with or without renal disease than in the controls. Moreover, serum OPN level correlated positively with disease activity index in both groups. In patients with renal disease, there was a positive correlation between IL-18 and OPN concentration ( p < 0.001). Also our study agreed with Rullo et al. (22) who found that increased circulating plasma OPN levels may be associated with organ damage in 42 pediatric SLE and 23 adult SLE. Plasma OPN concentrations were significantly higher in both groups than in controls and showed a positive correlation between OPN and SLEDAI in six months. In addition, Rullo et al. (22) showed that increased OPN is associated with higher titer of antibodies to ds-DNA (p < 0.001) and elevated IFN-α (p = 0.02), which were shown to be important in pathogenesis and clinical manifestations of SLE. Also other study showed elevated osteopontin serum levels in 101 SLE patients compared to 115 healthy controls. It is higher in those with a renal involvement (CKD and proteinuria), anemia, and increased inflammatory activity (23) . In this study we found positive significant correlation between OPN and CIMT in SLE patients. Similarly Maria et al also found significant positive correlation of plasma OPN concentration with CIMT(24). Osteopontin as a marker of subclinical atherosclerosis found no evidence of association between osteopontin levels and early vascular markers of atherosclerosis (carotid intima-media thickness, carotid elasticity) in asymptomatic young adults, suggesting that osteopontin is not implicated in the preclinical atherosclerotic changes in vascular structure and function (12) . Systemic immune and inflammatory diseases, such as systemic lupus erythematosus (SLE), are associated with increased morbidity and mortality, most of it attributable to cardiovascular events. Inflammation is associated with endothelial dysfunction, atherosclerosis, damage of the arterial wall and causes increased arterial stiffness. CIMT is proposed to demonstrate the subclinical atherosclerosis (25) . Our study found a significant correlation of CIMT as a marker of subclinical atherosclerosis with disease duration and serum cholesterol but no correlation with age, HDL or disease activity. This was agree with Andrea et al. (26) who did study on 63 patients with SLE and reported that there was significant correlation between CIMT and disease duration, age. In the present study we found no significant correlation between CIMT and SLEDAI in SLE patients. This opposite to study was done by Barbulescu et that correlation between pulse wave velocity and disease activity in these patients suggesting that disease flare or aggravation may play a permissive role in vascular injury through vascular inflammation and endothelial dysfunction, which will decrease arterial compliance(27).
CONCLUSION
serum level of OPN was higher in SLE patients and correlated with disease activity and CIMT, and can be used as a marker of subclinical atherosclerosis.
